17 hours Ago
Domestic pharma maker Mankind Pharma today announced their partnership with Innovent Biologics to exclusively license and sell sintilimab , an advanced PD-1 immunotherapy , in the Indian market. ET Year-end Special Reads Corporate Kalesh: Top family disputes of India Inc in 2024 The world of business lost these eminent people in 2024 Fast, faster, fastest: How 2024 put more speed into your shopping “This strategic collaboration aims to address the critical challenges in cancer treatment and improve patient access to innovative therapeutic options in the region,” the company said in a statement. According to The National Cancer Registry Programme Cancer has become a major health concern in India, with its burden projected to reach 29.
8 million DALYs by 2025. Sintilimab, marketed as TYVYT (sintilimab injection) in China, is a high-quality PD-1 immunoglobulin G4 monoclonal antibody co-developed by Innovent and Eli Lilly. Its mechanism of blocking the PD-1/PD-L1 pathway reactivates T-cells, enhancing the body's natural ability to target and eliminate cancer cells.
“The drug has demonstrated remarkable efficacy and favorable safety across multiple major cancer types with eight approved indications in China, including non-small cell lung cancer, liver cancer, gastric cancer, esophageal cancer, endometrial cancer and Hodgkin's lymphoma. TYVYT (sintilimab injection), is one of the top therapy choices in immunotherapy, has already benefited millions of cancer patients since its launch in 2018. This versatile immunotherapy holds the potential to make a significant impact for oncology patients in India,” the company said.
Web Development Maximizing Developer Productivity: The Pomodoro Technique in Practice By - Prince Patni, Software Developer (BI, Data Science) View Program Marketing Digital marketing - Wordpress Website Development By - Shraddha Somani, Digital Marketing Trainer, Consultant, Strategiest and Subject Matter expert View Program Artificial Intelligence(AI) Master in Python Language Quickly Using the ChatGPT Open AI By - Metla Sudha Sekhar, IT Specialist and Developer View Program Artificial Intelligence(AI) Tabnine AI Masterclass: Optimize Your Coding Efficiency By - Metla Sudha Sekhar, IT Specialist and Developer View Program Finance Financial Literacy for Non-Finance Executives By - CA Raja, Chartered Accountant | Financial Management Educator | Former AVP - Credit, SBI View Program Astrology Vastu Shastra Course By - Sachenkumar Rai, Vastu Shashtri View Program Design Microsoft Designer Guide: The Ultimate AI Design Tool By - Prince Patni, Software Developer (BI, Data Science) View Program Entrepreneurship From Idea to Product: A Startup Development Guide By - Dr. Anu Khanchandani, Startup Coach with more than 25 years of experience View Program Artificial Intelligence(AI) AI for Everyone: Understanding and Applying the Basics on Artificial Intelligence By - Ritesh Vajariya, Generative AI Expert View Program Marketing Digital Marketing Masterclass by Neil Patel By - Neil Patel, Co-Founder and Author at Neil Patel Digital Digital Marketing Guru View Program Artificial Intelligence(AI) Learn InVideo AI: Create Videos from Text Easily By - Prince Patni, Software Developer (BI, Data Science) View Program Finance A2Z Of Finance: Finance Beginner Course By - elearnmarkets, Financial Education by StockEdge View Program Data Analysis Learn Power BI with Microsoft Fabric: Complete Course By - Prince Patni, Software Developer (BI, Data Science) View Program Strategy Succession Planning Masterclass By - Nigel Penny, Global Strategy Advisor: NSP Strategy Facilitation Ltd. View Program Finance Value and Valuation Masterclass By - CA Himanshu Jain, Ex McKinsey, Moody's, and PwC, Co - founder, The WallStreet School View Program Marketing Digital Marketing Masterclass by Pam Moore By - Pam Moore, Digital Transformation and Social Media Expert View Program Office Productivity Advanced Excel Course - Financial Calculations & Excel Made Easy By - Anirudh Saraf, Founder- Saraf A & Associates, Chartered Accountant View Program Entrepreneurship Startup Fundraising: Essential Tactics for Securing Capital By - Dr.
Anu Khanchandani, Startup Coach with more than 25 years of experience View Program Artificial Intelligence(AI) ChatGPT Mastery from Zero to Hero: The Complete AI Course By - Metla Sudha Sekhar, IT Specialist and Developer View Program Data Science MySQL for Beginners: Learn Data Science and Analytics Skills By - Metla Sudha Sekhar, IT Specialist and Developer View Program Finance Tally Prime & GST Accounting: Complete Guide By - CA Raj K Agrawal, Chartered Accountant View Program Strategy ESG and Business Sustainability Strategy By - Vipul Arora, Partner, ESG & Climate Solutions at Sattva Consulting Author I Speaker I Thought Leader View Program Marketing Future of Marketing & Branding Masterclass By - Dr. David Aaker, Professor Emeritus at the Haas School of Business, UC Berkeley, Author | Speaker | Thought Leader | Branding Consultant View Program Under the agreement, Mankind Pharma will have exclusive rights to register, import, market, sell and distribute sintilimab in India. Innovent will oversee manufacturing and supply of the product, ensuring consistent availability and adherence to high-quality standards.
Innovent will be eligible to receive upfront, regulatory and commercial milestone payments. "By bringing this innovative therapy to the Indian market, we are committed to improving patient outcomes and reinforcing our position as a leader in oncology. Mankind Pharma brings its extensive pharmaceutical expertise and expansive distribution network to this partnership, with a robust field force of 16,000+ personnel and over 13,000 stockists across India.
This ecosystem will be crucial in ensuring widespread access to sintilimab across urban and rural markets. The partnership represents more than a commercial agreement – it's a commitment to transforming oncological care in India , making innovative treatments available to a broader patient population," said Atish Majumdar – Sr President – Sales & Marketing, Mankind Pharma Limited. Nominations for ET MSME Awards are now open.
The last day to apply is December 31, 2024. Click here to submit your entry for any one or more of the 22 categories and stand a chance to win a prestigious award. (You can now subscribe to our Economic Times WhatsApp channel ).
